Prognostic stratification based on m5C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma

Prognostic stratification based on m5C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma

BackgroundImmunotherapy is a promising anti-cancer strategy in hepatocellular carcinoma (HCC). However, a limited number of patients can benefit from it. There are currently no reliable biomarkers available to find the potential beneficiaries. Methylcytosine (m5C) is crucial in HCC, but its role in...

Full description

Bibliographic Details
Main Authors: Ping Liu, Ziqing Zhu, Jiayao Ma, Le Wei, Ying Han, Edward Shen, Xiao Tan, Yihong Chen, Changjing Cai, Cao Guo, Yinghui Peng, Yan Gao, Yongting Liu, Qiaoqiao Huang, Le Gao, Yin Li, Zhaohui Jiang, Wantao Wu, Yihan Liu, Shan Zeng, Wei Li, Ziyang Feng, Hong Shen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
m5C
immunotherapy
biomarker
drug sensitivity
HCC
precision medicine
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.951529/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.951529/full

Similar Items